Redaporfin (LUZ11) acts as a potent photosensitizer. Redaporfin causes direct antineoplastic effects as well as indirect immune‐dependent destruction of malignant lesions.In Vitro: The combination photodynamic therapy (PDT) with Redaporfin (5μM) induces a reduction in the abundance of several Golgi apparatus (GA) proteins such as Golgi brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1), golgin subfamily A member 2 (GOLGA2), and galactosyltransferase 1 (GALT1), as well as that of two ER proteins, eukaryotic translation initiation factor 2-alpha (eIF2α) kinase 3 (EIF2AK3) and protein disulfide-isomerase A3 (PDIA3). In contrast, there is no major decrease in mitochondrial import receptor subunit TOM20 homolog (TOMM20) or in the cytoskeleton protein β-actin.